Biohope is an early commercial stage R&D company dedicated to the development of precision medicine IVD tools and unique patient knowledge for chronic inflammatory conditions. Founded in 2015, it employs 22 professionals in R&D, IT, Medical Affairs, Financial, Legal, Regulatory, Quality Control and BD&L.
Biohope lead product, Immunobiogram®, is a novel and unique, patented in vitro diagnostic device which generates a report for the physicians to optimize each individual immunosuppressive therapy. It is a combination of a bioassay and database analysis tools .
The Immunobiogram® in Kidney Transplantation is the first product from our technological platform. We have successfully finished a National and an International clinical study (performed in Spain, USA, Germany, Denmark, Poland) that have demonstrated the effectiveness of Immunobiogram®
We have a patent published for the EU, a PCT ongoing, an ISO 13485 certification, and a CE mark (IVD-D) and a manufacturing & lab license. CE mark (IVD-R) expected 1Q2022.
In our pipeline, based on Immunobiogram® technology, adaptation is ongoing for Rheumatoid Arthritis, and planned for Lupus Nephritis. Further adaptations of the Immunobiogram® to other conditions that require a patient to be on immunosupressants (transplants of other organs, additional autoimmune diseases) will be assessed in the future.